Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC).

被引：1
|
作者：
Brahmer, Julie R.
Horn, Leora
Antonia, Scott J.
Spigel, David R.
Gandhi, Leena
Sequist, Lecia V.
Sankar, Vindira
Ahlers, Christoph Matthias
Wigginton, Jon M.
Kollia, Georgia
Gupta, Ashok Kumar
Gettinger, Scott N.
机构：
[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[3] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Massachusetts Gen Hosp, Boston, MA 02114 USA
[7] Bristol Myers Squibb Co, Princeton, NJ USA
[8] Yale Univ, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8030
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)
    Gettinger, S. N.
    Horn, L.
    Gandhi, L.
    Spigel, D. R.
    Antonia, S. J.
    Rizvi, N. A.
    Powderly, J. D.
    Heist, R. S.
    Carvajal, R. D.
    Jackman, D. M.
    Sequist, L. V.
    Smith, D. C.
    Leming, P. D.
    Topalian, S. L.
    Hodi, F.
    Sznol, M.
    Harbison, C. T.
    Kollia, G. D.
    Brahmer, J. R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S34 - S34
  • [2] Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer
    Rajan, Arun
    Gulley, James L.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2014, 3 (06) : 403 - 405
  • [3] NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC): OVERALL SURVIVAL AND LONG-TERM SAFETY IN A PHASE 1 TRIAL
    Brahmer, Julie R.
    Horn, Leora
    Antonia, Scott J.
    Spigel, David
    Gandhi, Leena
    Sequist, Lecia V.
    Sankar, Vindira
    Ahlers, Christoph M.
    Wigginton, Jon M.
    Kollia, Georgia
    Gupta, Ashok
    Gettinger, Scott N.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S365 - S366
  • [4] Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538)
    Sznol, Mario
    Kluger, Harriet M.
    Hodi, F. Stephen
    McDermott, David F.
    Carvajal, Richard D.
    Lawrence, Donald P.
    Topalian, Suzanne Louise
    Atkins, Michael B.
    Powderly, John D.
    Sharfman, William Howard
    Puzanov, Igor
    Smith, David C.
    Wigginton, Jon M.
    Kollia, Georgia
    Gupta, Ashok Kumar
    Sosman, Jeffrey Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).
    Sznol, Mario
    Kluger, Harriet M.
    Hodi, F. Stephen
    McDermott, David F.
    Carvajal, Richard D.
    Lawrence, Donald P.
    Topalian, Suzanne Louise
    Atkins, Michael B.
    Powderly, John D.
    Sharfman, William Howard
    Puzanov, Igor
    Smith, David C.
    Wigginton, Jon M.
    Kollia, Georgia
    Gupta, Ashok Kumar
    Sosman, Jeffrey Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
  • [6] EFFICACY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): SUBPOPULATION RESPONSE ANALYSIS IN A PHASE 1 TRIAL
    Gettinger, Scott
    Horn, Leora
    Antonia, Scott J.
    Spigel, David R.
    Gandhi, Leena
    Sequist, Lecia V.
    Sankar, Vindira
    Ahlers, Christoph M.
    Wigginton, Jon M.
    Kollia, Georgia
    Gupta, Ashok
    Brahmer, Julie R.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S909 - S909
  • [7] NIVOLUMAB (ANTI-PD-1; BMS-936558, ONO-4538) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): SURVIVAL AND CLINICAL ACTIVITY BY SUBGROUP ANALYSIS
    Rizvi, Naiyer A.
    Gettinger, Scott N.
    Horn, Leora
    Gandhi, Leena
    Spigel, David R.
    Powderly, John D.
    Heist, Rebecca S.
    Carvajal, Richard D.
    Jackman, David M.
    Sequist, Lecia V.
    Smith, David C.
    Leming, Philip D.
    Topalian, Suzanne L.
    Hodi, F. Stephen
    Sznol, Mario
    Harbison, Christopher T.
    Kollia, Georgia D.
    Brahmer, Julie R.
    Antonia, Scott J.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : S152 - S152
  • [8] Survival and long-term safety in patients (pts) with advanced solid tumors receiving nivolumab (anti-PD-1; BMS-936558; ONO-4538)
    Hodi, F. S.
    Topalian, S. L.
    Brahmer, J. R.
    McDermott, D. F.
    Smith, D. C.
    Gettinger, S.
    Taube, J. M.
    Pardoll, D. M.
    Wigginton, J. M.
    Sznol, M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S185 - S185
  • [9] Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial.
    Topalian, Suzanne Louise
    Sznol, Mario
    Brahmer, Julie R.
    McDermott, David F.
    Smith, David C.
    Gettinger, Scott N.
    Taube, Janis M.
    Drake, Charles G.
    Pardoll, Drew M.
    Powderly, John D.
    Carvajal, Richard D.
    Sosman, Jeffrey Alan
    Atkins, Michael B.
    Antonia, Scott J.
    Spigel, David R.
    Lawrence, Donald P.
    Kollia, Georgia
    Gupta, Ashok Kumar
    Wigginton, Jon M.
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy
    Rizvi, N. A.
    Antonia, S. J.
    Shepherd, F. A.
    Chow, L. Q.
    Goldman, J.
    Shen, Y.
    Chen, A. C.
    Gettinger, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S32 - S32
12345